Back to User profile » Dr Yinying Lu
Papers published by Dr Yinying Lu:
Predicting the Occurrence of Cachexia in Patients with BCLC Stage B/C Hepatocellular Carcinoma Receiving Systemic Therapy: A Nomogram Based on Common Clinical Parameters
Ma W, Han J, Yu H, Liang Z, Peng C, Lu Y
Journal of Hepatocellular Carcinoma 2025, 12:2845-2857
Published Date: 20 December 2025
A Multicenter Retrospective Study: Impact of First-Line Treatment Strategies on second-Line Efficacy and Safety of Regorafenib with or Without PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma
Ma W, Li Y, Lu Y, Liang Z, Yu H, Han J, Liu J, Wang W, Peng C, Cheng J
Journal of Hepatocellular Carcinoma 2025, 12:2123-2137
Published Date: 16 September 2025
Efficacy and Safety of Tyrosine Kinase Inhibitors Alone or Combination with Programmed Death-1 Inhibitors in Treating of Hepatitis C-Related Hepatocellular Carcinoma
Lei J, Yang S, Chen B, Zhang L, Yan T, Yang G, Chen Y, Li Y, Lu Y, Zuo S
Journal of Hepatocellular Carcinoma 2023, 10:357-367
Published Date: 2 March 2023
Risk Factors for Hepatic Encephalopathy in Hepatocellular Carcinoma After Sorafenib or Lenvatinib Treatment: A Real-World Study
Chen B, Zhang L, Cheng J, Wu T, Lei J, Yang X, Zhang R, Safadi R, Li Y, Si T, Lu Y
Drug Design, Development and Therapy 2022, 16:4429-4437
Published Date: 28 December 2022
Efficacy and Safety of TKI Plus PD-1 Inhibitors in Elderly uHCC Patients: A Retrospective Study
Chen B, Lei J, Zhao H, Dong J, Zeng Z, Li Y, Yu L, Zhou L, Jia A, Lu Y, Cheng J
Journal of Hepatocellular Carcinoma 2022, 9:1171-1185
Published Date: 8 November 2022
Response Stratification in the First-Line Combined Immunotherapy of Hepatocellular Carcinoma at Genomic, Transcriptional and Immune Repertoire Levels
Cheng J, Li Y, Wang X, Dong Z, Chen Y, Zhang R, Huang J, Jin X, Yao J, Ge A, Song L, Lu Y, Zeng Z
Journal of Hepatocellular Carcinoma 2021, 8:1281-1295
Published Date: 27 October 2021